Selected article for: "clinical trial and high activity"

Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
  • Document date: 2020_3_23
  • ID: j0i9ozsz_52
    Snippet: Favipiravir RNA-dependent RNA polymerase inhibitor with broad-spectrum antiviral activity; however, demonstrated high EC 50 (decreased potency) against SARS-CoV-2 but was effective in protecting mice against Ebola virus despite similarly high EC 50 values [3] . Currently being evaluated in Clinical Trial NCT04273763 for patients with COVID-19. This agent is not FDA approved or available in the United States......
    Document: Favipiravir RNA-dependent RNA polymerase inhibitor with broad-spectrum antiviral activity; however, demonstrated high EC 50 (decreased potency) against SARS-CoV-2 but was effective in protecting mice against Ebola virus despite similarly high EC 50 values [3] . Currently being evaluated in Clinical Trial NCT04273763 for patients with COVID-19. This agent is not FDA approved or available in the United States.

    Search related documents:
    Co phrase search for related documents